CLS publishes interim report January – March 2024
Summary of the interim report (relates to the Group) Three months (01/01/2024–03/31/2024) · Net sales totaled SEK 3,140,000 (SEK 587,000). · Profit/loss after financial items totaled SEK -12,397,000 (SEK -21,464,000). · Basic and diluted earnings per share totaled SEK -0.01 (SEK -0.15). · The equity ratio on March 31, 2024, was 81% (7.5%).Significant events in the first quarter of 2024 · An order for ClearPoint Prism Neuro Laser Therapy System products was received from ClearPoint Neuro, Inc (Nasdaq: CLPT), with an approximate value of SEK 8.1 million. · Mobile